Sodium zirconium cyclosilicate - Generic Drug Details

What are the generic sources for sodium zirconium cyclosilicate and what is the scope of patent protection?

Sodium zirconium cyclosilicate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium zirconium cyclosilicate has one hundred and thirty-eight patent family members in thirty-eight countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for sodium zirconium cyclosilicate

International Patents:	138
US Patents:	14
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	33
Patent Applications:	45
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sodium zirconium cyclosilicate
What excipients (inactive ingredients) are in sodium zirconium cyclosilicate?	sodium zirconium cyclosilicate excipients list
DailyMed Link:	sodium zirconium cyclosilicate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sodium zirconium cyclosilicate

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sodium zirconium cyclosilicate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mario Negri Institute for Pharmacological Research	PHASE3
Qianfoshan Hospital	PHASE4
Fundación para la Investigación del Hospital Clínico de Valencia	PHASE3

See all sodium zirconium cyclosilicate clinical trials

Generic filers with tentative approvals for SODIUM ZIRCONIUM CYCLOSILICATE

Applicant	Application No.	Strength	Dosage Form
		10G	POWDER, FOR SUSPENSION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for sodium zirconium cyclosilicate

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for SODIUM ZIRCONIUM CYCLOSILICATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOKELMA	for Oral Suspension	sodium zirconium cyclosilicate	5 g/packet and 10 g/packet	207078	5	2022-05-18

US Patents and Regulatory Information for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes

Expired US Patents for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018

EU/EMA Drug Approvals for sodium zirconium cyclosilicate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Lokelma	sodium zirconium cyclosilicate	EMEA/H/C/004029Lokelma is indicated for the treatment of hyperkalaemia in adult patients.	Authorised	no	no	no	2018-03-22

International Patents for sodium zirconium cyclosilicate

Country	Patent Number	Title	Estimated Expiration
Slovenia	2673237
Taiwan	201607543	Microporous zirconium silicate for the treatment of hyperkalemia
Slovenia	2673237
New Zealand	740931

Supplementary Protection Certificates for sodium zirconium cyclosilicate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1948158	16C0018	France		PRODUCT NAME: SACUBITRIL/VALSARTAN,SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN,C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL) PROPIONATE-(S)-3'-METHYL-2'-(PENTANOY(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE)DE TRISODIUM HEMIPENTAHYDRATE; REGISTRATION NO/DATE: EU/1/15/1058 20151123
0957929	SPC/GB06/021	United Kingdom		PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
2673237	SPC/GB19/027	United Kingdom		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REGISTERED: UK EU/1/17/1173(NI) 20180326; UK PLGB17901/0331-0001 20180326; UK PLGB17902/0332-0001 20180326
1856135	CA 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113

Sodium Zirconium Cyclosilicate: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What market does sodium zirconium cyclosilicate address?

Sodium zirconium cyclosilicate (SZC) is an oral, non-absorbed potassium binder used to treat hyperkalemia and support maintenance dosing after initial potassium lowering. Demand is driven by:

• Chronic kidney disease (CKD) and heart failure populations with recurring hyperkalemia risk from renin-angiotensin-aldosterone system inhibitors and other potassium-elevating regimens
• Hospital and emergency management of elevated serum potassium where rapid potassium reduction changes disposition and downstream resource use
• Longer-duration payer interest because maintenance therapy converts an episodic lab abnormality into a recurring treatment pattern

Commercial structure is concentrated around the brand Lokelma in the US and key international markets under Takeda’s ownership and commercialization arrangements (Takeda is the originator and commercial authority in most geographies).

---

What are the core market dynamics shaping growth?

1) Treatment algorithm shift toward potassium binders

SZC competes with other chronic and acute hyperkalemia strategies, but it has carved a role where rapid onset and tolerability drive clinician preference. Key dynamic is that potassium control becomes a measurable treatment endpoint rather than only “rescue” management, supporting repeat prescribing.

2) Maintenance dosing expands addressable use

Unlike one-off interventions, SZC supports a maintenance concept in which patients continue a binder to keep potassium in range. That changes the commercial math: once stabilized, the patient becomes a recurring demand engine through continued refills and dose adjustments.

3) Reimbursement and formulary penetration

Net sales trajectory depends on:

• Formulary inclusion within nephrology and cardiology treatment pathways
• Prior authorization behavior and utilization management tied to baseline potassium criteria and CKD/heart failure diagnoses
• Copay support and patient access programs that reduce discontinuation risk

4) Competition pressure

The category has multiple players. Competitive dynamics include:

• Price and rebate positioning among newer oral binders
• Differentiation on dosing convenience, onset expectations, and adverse event profiles
• Local payer education and guideline-aligned placement

---

What is the financial trajectory?

No complete, consistent set of public financial data at the single-product level (SZC/Lokelma net sales by year, segmented by geography) is available in the source set provided in this request. As a result, the product-level financial trajectory cannot be stated with hard year-by-year numbers.

What can be stated as directionally actionable on financial trajectory mechanics, based on commercial drivers:

• Volume-driven growth is the primary lever because SZC is dosed chronically for maintenance. If prescribing shifts toward maintenance and adherence holds, unit demand compounds.
• Contracting and reimbursement determine gross-to-net. Increased formulary access typically expands the market faster than it changes wholesale list pricing, so gross-to-net management matters as much as top-line volume.
• Seasonality and lab testing cadence influence payer claims timing, particularly for maintenance patients whose physician visits and lab monitoring create refill rhythms.
• Competitive share changes affect both net sales growth rate and margin via rebates and access programs.

---

How does pricing and net-to-gross typically evolve in this category?

SZC pricing outcomes are governed by three recurring forces:

1. Rebate intensification as penetration increases
   As a product moves from early access to broader managed care coverage, payer systems often demand larger rebates tied to utilization.

2. Patient access program leverage
   Copay or assistance programs can sustain conversion from “eligible” to “treated,” but they can shift payer mix and affect net collections.

3. Mix shift toward maintenance dosing
   Maintenance regimens generally increase total days of therapy, but dosing frequency and titration behavior alter the average patient daily dose, affecting realized revenue per treated patient.

---

What are the key demand-side indicators investors and operators track?

Even without full product financials in the provided dataset, these indicators reliably forecast revenue trajectory for SZC:

Prescribing and patient mix

• Percent of patients on maintenance vs acute/initial-only dosing
• Average daily dose and duration of therapy (titration patterns)
• Persistence and refill cadence (discontinuation after stabilization is a common drag in chronic therapies)

Access

• Formulary tier placement and uptake across national and regional payers
• Prior authorization frequency and denial rates
• Coverage for CKD vs heart failure subpopulations where clinical pathways overlap

Utilization

• Claims volume trends as a proxy for treated patients
• Geographic diffusion into health systems and large distributor networks

---

What are the major commercial risks and upside levers?

Risks

• Competitive displacement if rival binders show better payer coverage or clinician preference in key subgroups
• Maintenance underutilization if prescribers stabilize potassium and then stop therapy early
• Reimbursement tightening if payer criteria become more restrictive for chronic use
• Safety/tolerability perceptions that can influence adherence and dosing continuity

Upside levers

• Guideline and pathway reinforcement that positions SZC earlier in the hyperkalemia course
• Broader CKD and heart failure coverage that increases treatable addressable populations
• Improved persistence through dosing protocols that reduce early drop-off after stabilization
• Contract wins that improve net pricing stability

---

Competitive landscape: how share translates into revenue

SZC’s revenue trajectory is sensitive to competitive share because binders are close substitutes in practice patterns. Share changes transmit quickly into top-line because:

• A patient treated with one binder can often switch if coverage changes or clinical outcomes shift.
• Maintenance patients are “sticky,” so gaining early maintenance share can create compounding unit demand.
• Payer-driven switching often targets cost, which means rebate and access negotiations are central to financial trajectory.

---

Key Takeaways

• Sodium zirconium cyclosilicate (Lokelma) targets hyperkalemia with a commercial model that can scale through maintenance dosing, turning episodic labs into recurring therapy.
• Market growth depends on formulary access, reimbursement behavior, and persistence, not only initial prescribing.
• Financial trajectory is driven by volume (days of therapy), gross-to-net contracting, and mix shift toward maintenance dosing.
• Product-level annual net sales cannot be stated from the information available in the provided request set; the actionable insight is that performance will track directly to access penetration and maintenance persistence rather than one-time uptake.

---

FAQs

1. What drives demand for sodium zirconium cyclosilicate?
   Recurring treatment needs in CKD and heart failure populations where potassium-elevating regimens increase hyperkalemia risk, plus the ability to use SZC as maintenance after initial correction.

2. Why does maintenance dosing matter financially?
   Maintenance increases days of therapy per patient and supports refill-based unit growth, shifting the revenue model from episodic to recurring.

3. What is the biggest determinant of net revenue?
   Gross-to-net outcomes from payer rebates, formulary status, and utilization management tied to baseline potassium criteria and diagnoses.

4. How does competition typically affect SZC’s market trajectory?
   Competitive switching and payer access changes can shift treated patient share quickly, especially for maintenance patients.

5. Which KPIs best predict SZC revenue trend?
   Treated patient claims volume, persistence/refill cadence, percentage on maintenance dosing, and formulary access changes across major payers.

---

References

[1] FDA. “Lokelma (sodium zirconium cyclosilicate) prescribing information.” U.S. Food and Drug Administration.
[2] Takeda. “Lokelma (sodium zirconium cyclosilicate) product information and commercialization materials.” Takeda.
[3] KDIGO. “Clinical Practice Guidelines for the Management of Chronic Kidney Disease.” Kidney Disease: Improving Global Outcomes (KDIGO).
[4] European Society of Cardiology (ESC) and related guideline publications on hyperkalemia management.